- Touchlight has expanded its mbDNA™ platform with three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
- The additions enhance flexibility, stability, and performance in gene editing and expression applications.
Touchlight has announced the expansion of its mbDNA™ platform with three new circular DNA architectures—sscDNA, hsscDNA, and dscDNA—broadening its portfolio of cell-free DNA solutions for gene editing and expression.
The new constructs complement the mbDNA technology introduced earlier this year, creating a more versatile system to address the limitations of traditional gene editing tools. The company stated that the platform offers enhanced stability, reduced immunogenicity, and compatibility with a range of gene insertion and expression technologies.
Produced using Touchlight’s cell-free enzymatic platform, mbDNA delivers high purity and low immunogenicity while achieving homology-directed repair (HDR) efficiency of 60–75% in primary T cells. The technology supports payloads of up to 20kb, enabling the delivery of large genetic cargos for advanced therapeutic applications.
The new DNA designs offer varying configurations: sscDNA as fully single-stranded, hsscDNA containing custom double-stranded regions, and dscDNA as fully double-stranded circular DNA. These formats allow for bespoke optimisation in applications such as transposase, recombinase, and episomal expression systems.
“mbDNA is a market-leading technology providing the best-in-class HDR template available today. With the addition of sscDNA, hsscDNA, and dscDNA, we’re empowering researchers and developers to unlock new possibilities in gene editing and therapeutic innovation.”
Karen Fallen, CEO at Touchlight
